CD8A and melanoma: The phenotypes of T cells have also been studied, and the ratio of reinvigorated CD8+ T cell to the tumor burden [85], as well as the activation status of both CD4+ and CD8+ T cells [86], upon treatment could predict for response to ICB in melanoma patients.